A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Platysma Prominence Clinical Trial

Official title:
Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

Status Completed

Clinical Trial Summary

This is a Phase 3, open-label study to evaluate the safety of BOTOX Injection in Adult Participants with Platysma Prominence

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Platysma Prominence

Clinical Trial Details

NCT number	NCT05134649
Study type	Interventional
Source	AbbVie
Contact
Status	Completed
Phase	Phase 3
Start date	November 17, 2021
Completion date	August 18, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05773053` - A Study of NT 201 Doses in the Treatment of Platysma Prominence	Phase 2
Completed	`NCT04949399` - A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence	Phase 3
Completed	`NCT04994535` - A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence	Phase 3
Completed	`NCT03915067` - BOTOX® for the Treatment of Platysma Prominence	Phase 2